Intratumoral CMP-001 is being investigated as monotherapy and in combination with pembrolizumab in patients with PD-(L)1 inhibitor-refractory advanced melanoma in an ongoing, dose-escalation, phase 1b study (NCT02680184). Here, CD274 is linked to melanoma.